Clinical Neurology and Neurosurgery
Volume 112, Issue 7 , Pages 602-608 , September 2010

Antiphospholipid syndrome and central nervous system

  • Miroslav Mayer

      Affiliations

    • University Hospital Center Zagreb, University of Zagreb, School of Medicine, Department of Medicine, Division of Clinical Immunology and Rheumatology, Kispaticeva ulica 12, 10000 Zagreb, Croatia
    • Corresponding Author InformationCorresponding author. Tel.: +385 12388330.
    • ,
  • Mislav Cerovec

      Affiliations

    • University Hospital Center Zagreb, University of Zagreb, School of Medicine, Department of Medicine, Division of Clinical Immunology and Rheumatology, Kispaticeva ulica 12, 10000 Zagreb, Croatia
    • ,
  • Marko Radoš

      Affiliations

    • University Hospital Center Zagreb, University of Zagreb, School of Medicine, Department of Diagnostic and Interventional Radiology, Kispaticeva ulica 12, 10000 Zagreb, Croatia
    • ,
  • Nada Čikeš

      Affiliations

    • University Hospital Center Zagreb, University of Zagreb, School of Medicine, Department of Medicine, Division of Clinical Immunology and Rheumatology, Kispaticeva ulica 12, 10000 Zagreb, Croatia

Received 10 March 2010 ,Accepted 23 March 2010.

References 

  1. Khamashta MA, Bertolaccini ML, Hughes GRV. Antiphospholipid (Hughes) syndrome. Autoimmunity. 2004;37:309–312
  2. Hughes G. Connective tissue disease and the skin. Clin Exp Dermatol. 1984;9:535–544
  3. Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette JC, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum. 1999;42:1309–1311
  4. Arnson Y, Shoenfeld Y, Alon E, Amital H. The antiphospholipid syndrome as a neurological disease. Semin Arthritis Rheum. 2009;
  5. Cervera R, Piette J, Font J, Khamashta MA, Shoenfeld Y, Camps MT, et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum. 2002;46:1019–1027
  6. Ferreira S, D’Cruz DP, Hughes GRV. Multiple sclerosis, neuropsychiatric lupus and antiphospholipid syndrome: where do we stand?. Rheumatology (Oxford). 2005;44:434–442
  7. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4:295–306
  8. Meroni P, Tincani A, Alarcon-Riquelme M, Shoenfeld Y, Borghi M. European forum on antiphospholipid antibodies: research in progress. Lupus. 2009;18:924–929
  9. Uthman I, Khamashta M. Ethnic and geographical variation in antiphospholipid (Hughes) syndrome. Ann Rheum Dis. 2005;64:1671–1676
  10. Galli M, Borrelli G, Jacobsen EM, Marfisi RM, Finazzi G, Marchioli R, et al. Clinical significance of different antiphospholipid antibodies in the WAPS (warfarin in the antiphospholipid syndrome) study. Blood. 2007;110:1178–1183
  11. Lutters BCH, Meijers JCM, Derksen RHWM, Arnout J, de Groot PG. Dimers of β2-glycoprotein I mimic thein vitro effects of β2-glycoprotein I–anti-β2-glycoprotein I antibody complexes. J Biol Chem. 2001;276:3060–3067
  12. Espinosa G, Cervera R. Antiphospholipid syndrome. Arthritis Res Ther. 2008;10:230
  13. Vega-Ostertag ME, Raschi E, Liu X, Romay-Penabad Z, De Micheli V, Galli M, et al. Toll-like receptor and antiphospholipid mediated thrombosis: in vivo studies. Ann Rheum Dis. 2007;66:1327–1333
  14. Cockrell E, Espinola R, McCrae K. Annexin A2: biology and relevance to the antiphospholipid syndrome. Lupus. 2008;17:944–952
  15. Pennings MTT, Derksen RHWM, Van Lummel M, Adelmeijer J, Vanhoorelbeke K, Urbanus RT, et al. Platelet adhesion to dimeric β2-glycoprotein I under conditions of flow is mediated by at least two receptors: glycoprotein Ibα and apolipoprotein E receptor 2. J Thrombosis Haemostasis. 2007;5:369–377
  16. Lin W, Chen P, Yang C, Cho E, Hahn BH, Grossman J, et al. Some antiphospholipid antibodies recognize conformational epitopes shared by β2-glycoprotein I and the homologous catalytic domains of several serine proteases. Arthritis Rheum. 2007;56:1638–1647
  17. Salmon J, de Groot P. Pathogenic role of antiphospholipid antibodies. Lupus. 2008;17:405–411
  18. Pierangeli SS, Girardi G, Vega-Ostertag M, Liu X, Espinola RG, Salmon J. Requirement of activation of complement C3 and C5 for antiphospholipid antibody-mediated thrombophilia. Arthritis Rheum. 2005;52:2120–2124
  19. Fischetti F. Thrombus formation induced by antibodies to 2-glycoprotein I is complement dependent and requires a priming factor. Blood. 2005;106:2340–2346
  20. Redecha P, Tilley R, Tencati M, Salmon JE, Kirchhofer D, Mackman N, et al. Tissue factor: a link between C5a and neutrophil activation in antiphospholipid antibody-induced fetal injury. Blood. 2007;110:2423–2431
  21. Staub H, Franck M, Ranzolin A, Norman G, Iverson G, von Mühlen C. IgA antibodies to beta2-glycoprotein I and atherosclerosis. Autoimmun Rev. 2006;6:104–106
  22. Roman MJ, Shanker B, Davis A, Lockshin MD, Sammaritano L, Simantov R, et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med. 2003;349:2399–2406
  23. Pereira J, Alfaro G, Goycoolea M, Quiroga T, Ocqueteau M, Massardo L, et al. Circulating platelet-derived microparticles in systemic lupus erythematosus. Association with increased thrombin generation and procoagulant state. Thromb Haemostatis. 2005;
  24. Distler JHW, Huber LC, Gay S, Distler O, Pisetsky DS. Microparticles as mediators of cellular cross-talk in inflammatory disease. Autoimmunity. 2006;39:683–690
  25. Martínez-Cordero E, Rivera García BE, Aguilar León DE. Anticardiolipin antibodies in serum and cerebrospinal fluid from patients with systemic lupus erythematosus. J Invest Allergol Clin Immunol. 1997;7:596–601
  26. Chapman J, Cohen-Armon M, Shoenfeld Y, Korczyn AD. Antiphospholipid antibodies permeabilize and depolarize brain synaptoneurosomes. Lupus. 1999;8:127–133
  27. Provenzale JM, Barboriak DP, Allen NB, Ortel TL. Patients with antiphospholipid antibodies: CT and MR findings of the brain. AJR Am J Roentgenol. 1996;167:1573–1578
  28. Provenzale JM, Ortel TL, Allen NB. Systemic thrombosis in patients with antiphospholipid antibodies: lesion distribution and imaging findings. AJR Am J Roentgenol. 1998;170:285–290
  29. Theodoridou A, Settas L. Demyelination in rheumatic diseases. Postgrad Med J. 2008;84:127–132
  30. Bot JCJ, Barkhof F, à Nijeholt GL, van Schaardenburg D, Voskuyl AE, Ader HJ, et al. Differentiation of multiple sclerosis from other inflammatory disorders and cerebrovascular disease: value of spinal mr imaging1. Radiology. 2002;223:46–56
  31. Sanna G, Bertolaccini ML, Hughes GRV. Hughes syndrome, the antiphospholipid syndrome: a new chapter in neurology. Ann NY Acad Sci. 2005;1051:465–486
  32. Krnic-Barrie S, O’Connor CR, Looney SW, Pierangeli SS, Harris EN. A retrospective review of 61 patients with antiphospholipid syndrome: analysis of factors influencing recurrent thrombosis. Arch Intern Med. 1997;157:2101–2108
  33. Shah NM, Khamashta MA, Atsumi T, Hughes GR. Outcome of patients with anticardiolipin antibodies: a 10 year follow-up of 52 patients. Lupus. 1998;7:3–6
  34. Sastre-Garriga J, Montalban X. APS and the brain. Lupus. 2003;12:877–882
  35. Terashi H, Uchiyama S, Hashimoto S, Miyazaki K, Tsutsumi Y, Yamazaki M, et al. Clinical characteristics of stroke patients with antiphospholipid antibodies. Cerebrovasc Dis. 2005;19:384–390
  36. Hughes GRV. Migraine, memory loss, and “multiple sclerosis”. Neurological features of the antiphospholipid (Hughes’) syndrome. Postgrad Med J. 2003;79:81–83
  37. Montalbán J, Rio J, Khamastha M, Davalos A, Codina M, Swana GT, et al. Value of immunologic testing in stroke patients. A prospective multicenter study. Stroke. 1994;25:2412–2415
  38. Krause I, Lev S, Fraser A, Blank M, Lorber M, Stojanovich L, et al. Close association between valvar heart disease and central nervous system manifestations in the antiphospholipid syndrome. Ann Rheum Dis. 2005;64:1490–1493
  39. Brey RL, Abbott RD, Curb JD, Sharp DS, Ross GW, Stallworth CL, et al. Beta(2)-glycoprotein 1-dependent anticardiolipin antibodies and risk of ischemic stroke and myocardial infarction: the honolulu heart program. Stroke. 2001;32:1701–1706
  40. Galli M, Luciani D, Bertolini G, Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood. 2003;101:1827–1832
  41. Sanna G, Bertolaccini ML, Cuadrado MJ, Laing H, Khamashta MA, Mathieu A, et al. Neuropsychiatric manifestations in systemic lupus erythematosus: prevalence and association with antiphospholipid antibodies. J Rheumatol. 2003;30:985–992
  42. Schellong SM, Weissenborn K, Niedermeyer J, Wollenhaupt J, Sosada M, Ehrenheim C, et al. Classification of Sneddon's syndrome. VASA. 1997;26:215–221
  43. Hilton DA, Footitt D. Neuropathological findings in Sneddon's syndrome. Neurology. 2003;60:1181–1182
  44. Francès C, Piette JC. The mystery of Sneddon syndrome: relationship with antiphospholipid syndrome and systemic lupus erythematosus. J Autoimmun. 2000;15:139–143
  45. Briley DP, Coull BM, Goodnight SH. Neurological disease associated with antiphospholipid antibodies. Ann Neurol. 1989;25:221–227
  46. Takanashi J, Sugita K, Miyazato S, Sakao E, Miyamoto H, Niimi H. Antiphospholipid antibody syndrome in childhood strokes. Pediatr Neurol. 1995;13:323–326
  47. Yamashita S, Iwamoto H, Hara M, Arai N. Infantile spongiform leukoencephalopathy: clinical and neuropathologic findings. Pediatr Neurol. 2002;27:217–220
  48. Cuadrado MJ, Khamashta MA, Ballesteros A, Godfrey T, Simon MJ, Hughes GR. Can neurologic manifestations of Hughes (antiphospholipid) syndrome be distinguished from multiple sclerosis? Analysis of 27 patients and review of the literature. Medicine (Baltimore). 2000;79:57–68
  49. Arnold DL, Matthews PM. MRI in the diagnosis and management of multiple sclerosis. Neurology. 2002;58:S23–31
  50. Cikes N, Bosnic D, Sentic M. Non-MS autoimmune demyelination. Clin Neurol Neurosurg. 2008;110:905–912
  51. Rovaris M, Viti B, Ciboddo G, Gerevini S, Capra R, Iannucci G, et al. Brain involvement in systemic immune mediated diseases: magnetic resonance and magnetisation transfer imaging study. J Neurol Neurosurg Psychiatr. 2000;68:170–177
  52. Khamashta MA, Cuadrado MJ, Mujic F, Taub NA, Hunt BJ, Hughes GR. The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med. 1995;332:993–997
  53. Shoenfeld Y, Lev S, Blatt I, Blank M, Font J, von Landenberg P, et al. Features associated with epilepsy in the antiphospholipid syndrome. J Rheumatol. 2004;31:1344–1348
  54. Chapman J, Soloveichick L, Shavit S, Shoenfeld Y, Korczyn AD. Antiphospholipid antibodies bind ATP: a putative mechanism for the pathogenesis of neuronal dysfunction. Clin Dev Immunol. 2005;12:175–180
  55. Liou HH, Wang CR, Chou HC, Arvanov VL, Chen RC, Chang YC, et al. Anticardiolipin antisera from lupus patients with seizures reduce a GABA receptor-mediated chloride current in snail neurons. Life Sci. 1994;54:1119–1125
  56. Nived O, Sturfelt G, Liang MH, De Pablo P. The ACR nomenclature for CNS lupus revisited. Lupus. 2003;12:872–876
  57. ACR AD HOC Committee On Neuropsychiatric Lupus . The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum. 1999;42:599–608
  58. Cuadrado MJ, Khamashta MA, Hughes GR. Migraine and stroke in young women. QJM. 2000;93:317–318
  59. Cervera R, Asherson RA, Font J, Tikly M, Pallarés L, Chamorro A, et al. Chorea in the antiphospholipid syndrome. Clinical, radiologic, and immunologic characteristics of 50 patients from our clinics and the recent literature. Medicine (Baltimore). 1997;76:203–212
  60. Hanly JG, McCurdy G, Fougere L, Douglas J, Thompson K. Neuropsychiatric events in systemic lupus erythematosus: attribution and clinical significance. J Rheumatol. 2004;31:2156–2162
  61. Denburg SD, Carbotte RM, Ginsberg JS, Denburg JA. The relationship of antiphospholipid antibodies to cognitive function in patients with systemic lupus erythematosus. J Int Neuropsychol Soc. 1997;3:377–386
  62. Tektonidou MG, Varsou N, Kotoulas G, Antoniou A, Moutsopoulos HM. Cognitive deficits in patients with antiphospholipid syndrome: association with clinical, laboratory, and brain magnetic resonance imaging findings. Arch Intern Med. 2006;166:2278–2284
  63. Menon S, Jameson-Shortall E, Newman SP, Hall-Craggs MR, Chinn R, Isenberg DA. A longitudinal study of anticardiolipin antibody levels and cognitive functioning in systemic lupus erythematosus. Arthritis Rheum. 1999;42:735–741
  64. Katzav A, Pick CG, Korczyn AD, Oest E, Blank M, Shoenfeld Y, et al. Hyperactivity in a mouse model of the antiphospholipid syndrome. Lupus. 2001;10:496–499
  65. Hughes GR, Cuadrado MJ, Khamashta MA, Sanna G. Headache and memory loss: rapid response to heparin in the antiphospholipid syndrome. Lupus. 2001;10:778
  66. Shoenfeld Y, Cervera R. Asherson's syndrome of the catastrophic antiphospholipid antibodies. J Rheumatol. 2008;35:2066–2068
  67. Cervera R, Bucciarelli S, Plasín MA, Gómez-Puerta JA, Plaza J, Pons-Estel G, et al. Catastrophic antiphospholipid syndrome (CAPS): descriptive analysis of a series of 280 patients from the “CAPS Registry”. J Autoimmun. 2009;32:240–245
  68. Sanna G, Bertolaccini ML, Khamashta MA. Neuropsychiatric involvement in systemic lupus erythematosus: current therapeutic approach. Curr Pharm Des. 2008;14:1261–1269
  69. Okuma H, Kitagawa Y, Yasuda T, Tokuoka K, Takagi S. Comparison between single antiplatelet therapy and combination of antiplatelet and anticoagulation therapy for secondary prevention in ischemic stroke patients with antiphospholipid syndrome. 2010;
  70. Lockshin MD, Erkan D. Treatment of the antiphospholipid syndrome. N Engl J Med. 2003;349:1177–1179
  71. Ruffatti A, Ross TD, Ciprian M, Nuzzo M, Rampudda M, Bertero MT, et al. Risk factors for a first thrombotic event in antiphospholipid antibody carriers. A multicentre, retrospective follow-up study. Ann Rheum Dis. 2009;68:397–399
  72. Petri M. Thrombosis and systemic lupus erythematosus: the Hopkins Lupus Cohort perspective. Scand J Rheumatol. 1996;25:191–193
  73. Jajoria P, Murthy V, Papalardo E, Romay-Penabad Z, Gleason C, Pierangeli SS. Statins for the Treatment of Antiphospholipid Syndrome?. Ann NY Acad Sci. 2009;1173:736–745
  74. Khamashta MA, Hunt BJ. Moderate dose oral anticoagulant therapy in patients with the antiphospholipid syndrome? No. J Thromb Haemostasis. 2005;3:844–845
  75. Rubenstein E, Arkfeld DG, Metyas S, Shinada S, Ehresmann S, Liebman HA. Rituximab treatment for resistant antiphospholipid syndrome. J Rheumatol. 2006;33:355–357
  76. Sanna G, Bertolaccini ML, Mathieu A. Central nervous system lupus: a clinical approach to therapy. Lupus. 2003;12:935–942

PII: S0303-8467(10)00094-6

doi: 10.1016/j.clineuro.2010.03.023

Clinical Neurology and Neurosurgery
Volume 112, Issue 7 , Pages 602-608 , September 2010

Article Tools

* Image Usage & Resolution